HIGH-DOSE BCNU WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) AND LOCALIZED RADIOTHERAPY FOR PATIENTS WITH HIGH-GRADE ASTROCYTOMAS

被引：0
|
作者：
COLOMBAT, P
LINASSIER, C
CALAIS, G
VELUT, S
SAUDEAU, D
DETOFFOL, B
JAN, M
AUTRET, A
LAMAGNERE, JP
BIRON, P
机构：
[1] CHU BRETONNEAU,DEPT HAEMATOL,F-37044 TOURS,FRANCE
[2] CHU TOURS,DEPT RADIOTHERAPY,F-37033 TOURS,FRANCE
[3] CHU TOURS,DEPT NEUROSURG,F-37033 TOURS,FRANCE
[4] CHU TOURS,DEPT NEUROL,F-37033 TOURS,FRANCE
[5] CTR LEON BERARD,BONE MARROW UNIT,F-69373 LYON,FRANCE
来源：
BONE MARROW TRANSPLANTATION | 1992年 / 10卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [31] HIGH-DOSE CHEMOTHERAPY WITHOUT AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN MELANOMA
    TCHEKMEDYIAN, NS
    TAIT, N
    VANECHO, D
    AISNER, J
    JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (12) : 1811 - 1818
  • [32] HIGH-DOSE THIOTEPA WITH BONE-MARROW TRANSPLANTATION AND LOCALIZED RADIOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED GLIOBLASTOMA-MULTIFORME
    AHMED, T
    COOK, P
    HELSON, L
    NIAZI, Z
    RAZIS, E
    SINGH, B
    MITTELMAN, A
    PUCCIO, C
    MOORTHY, C
    LANSEN, T
    KASOFF, S
    ARLIN, Z
    JOURNAL OF CHEMOTHERAPY, 1993, 5 : 741 - 742
  • [33] ESCALATING THE MELPHALAN DOSE IN A REGIMEN INCLUDING HIGH-DOSE ETOPOSIDE FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IS NOT ASSOCIATED WITH ENHANCED TOXICITY
    SHER, GD
    COLWILL, R
    COUTURE, F
    STEWART, K
    CRUMP, M
    KEATING, A
    EXPERIMENTAL HEMATOLOGY, 1993, 21 (08) : 1130 - 1130
  • [34] HIGH-GRADE PYREXIA FOLLOWING BONE-MARROW TRANSPLANTATION AS A NEUROTOXIC COMPLICATION OF HIGH-DOSE CHEMOTHERAPY AND RADIOTHERAPY IN THE UKALL-XII TRIAL
    MURPHY, P
    PARKER, A
    HUTCHINSON, RM
    BONE MARROW TRANSPLANTATION, 1994, 13 (02) : 229 - 230
  • [35] ERYTHROPOIETIC ACTIVITY IN PATIENTS TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    LITTLEWOOD, TJ
    BENTLEY, DP
    CAVILL, I
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 563 - 563
  • [36] HIGH-DOSE AMSA AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION (AMBT) IN PATIENTS WITH SOLID TUMORS
    ZANDER, A
    SPITZER, G
    LEGHA, S
    DICKE, K
    VELLEKOOP, L
    VERMA, D
    MINNHAAR, G
    SCHELL, F
    BLUMENSCHEIN, G
    BODEY, G
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 234 - 234
  • [37] AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) AFTER HIGH-DOSE CYCLOPHOSPHAMIDE, MITOXANTRONE, ALKERAN (CMA) IN BREAST-CANCER
    GISSELBRECHT, C
    DEVAUX, Y
    EXTRA, JM
    LOTZ, JP
    GUILLEVIN, L
    BREMOND, D
    JANVIER, M
    MARANINCHI, D
    BONE MARROW TRANSPLANTATION, 1992, 10 : 36 - 36
  • [38] HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN POOR PROGNOSIS NON-HODGKINS LYMPHOMAS (NHL)
    LAMAGNERE, JP
    COLOMBAT, P
    BINET, C
    DESBOIS, I
    BABAULT, C
    CALAIS, G
    REISENLEITER, M
    DOMENECH, J
    BONE MARROW TRANSPLANTATION, 1988, 3 : 82 - 82
  • [39] HIGH-DOSE THERAPY FOLLOWED BY AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN PREVIOUSLY UNTREATED NON-HODGKINS-LYMPHOMA
    TURA, S
    MAZZA, P
    GHERLINZONI, F
    RICCI, P
    VISANI, G
    BANDINI, G
    ZACCARIA, A
    ROSTI, G
    LAURIA, F
    BACCARANI, M
    ZINZANI, PL
    POLETTI, G
    MOTTA, MR
    RIZZI, S
    VERLICCHI, F
    FINELLI, C
    SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 1986, 37 (04): : 347 - 352
  • [40] HIGH-DOSE MELPHALAN AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HIGH-RISK MYELOMA
    HAROUSSEAU, JL
    MILPIED, N
    GARAND, R
    BOURHIS, JH
    BRITISH JOURNAL OF HAEMATOLOGY, 1987, 67 (04) : 493 - 493
12345